What is Talphera?
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company dedicated to developing and commercializing therapies for medically supervised settings. Headquartered in San Mateo, California, the company's pipeline includes Niyad, an investigational anticoagulant for extracorporeal circuits, and LTX-608, a potential treatment for conditions like DIC and ARDS. Talphera also offers Fedsyra and PFS-02, pre-filled syringes for ephedrine and phenylephrine, respectively. The company's focus on critical care and procedural medications positions it within a vital segment of the healthcare market.
How much funding has Talphera raised?
Talphera has raised a total of $46M across 2 funding rounds:
Stock/Share Issuance
$29M
Private Equity
$17M
Stock/Share Issuance (2025): $29M, investors not publicly disclosed
Private Equity (2025): $17M, investors not publicly disclosed
What's next for Talphera?
The substantial enterprise-level capital infusion suggests Talphera is poised for significant scaling and advancement of its therapeutic candidates. This strategic backing will likely accelerate clinical development, regulatory submissions, and potential commercialization efforts for its lead products. The company's ability to attract major investment indicates strong confidence in its scientific approach and market strategy, paving the way for future growth and expansion within the specialty pharmaceutical landscape.
See full Talphera company page
